NRG1 and Schizophrenia Treatment

ANS 2012 Oral Presentation

Presented at: Annual Meeting of the Australian Neuroscience Society 2012, Gold Coast , Australia.

Please read on for details of the references I mentioned throughout my presentation:

Bertram, I. et al., 2007. Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Annals of the New York Academy of Sciences, 1096, pp.147-156.

Chong, V.Z. et al., 2008. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res, 100(1-3), pp.270-80.

Gao, R. et al., 2010. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. Journal of the American College of Cardiology, 55(18), pp.1907-1914.

Hahn, C.-G. et al., 2006. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature Medicine, 12(7), pp.824-828.

Jones, C.A., Watson, D.J.G. & Fone, K.C.F., 2011. Animal models of schizophrenia. British Journal of Pharmacology, 164(4), pp.1162-1194.

Kwon, O.B. et al., 2008. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proceedings of the National Academy of Sciences of the United States of America, 105(40), pp.15587-15592.

Mei, L. & Xiong, W.-C., 2008. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nature Reviews. Neuroscience, 9(6), pp.437-452.

Mouri, A. et al., 2007. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int, 51(2-4), pp.173-84.

Nicodemus, K.K. et al., 2009. A 5’ promoter region SNP in NRG1 is associated with schizophrenia risk and type III isoform expression. Molecular Psychiatry, 14(8), pp.741-743.

Perry, W. et al., 2009. A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Archives of General Psychiatry, 66(10), pp.1072-1080.

Shibuya, M. et al., 2010. Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. Journal of Neural Transmission (Vienna, Austria: 1996), 117(7), pp.887-895.

Stefansson, H. et al., 2002. Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics, 71(4), pp.877-892.

Walss-Bass, C. et al., 2006. A novel missense mutation in the transmembrane domain of neuregulin 1 is associated with schizophrenia. Biological Psychiatry, 60(6), pp.548-553.


Print Friendly, PDF & Email

Comments are closed.